The paper stack was four feet high, maybe more. The junior reviewer, let’s call her Priya, didn’t look up. She felt the weight of it in her desk chair-not just the physical weight of the submission for the new high-risk device, but the weight of the ninety-day clock ticking down to zero. Ninety days to review documentation provided entirely by the company whose quarterly profits depended on her approval. And this was just one of the 47 files she was juggling that quarter.

I’ll admit, I used to believe it. I used to trust the label like it was scripture. If the package said ‘safe’ and had the official seal, I mentally checked that box and moved on. That was my mistake-the one I have to acknowledge before I can even begin to criticize the system. I outsourced my critical thinking to a bureaucratic process I didn’t understand, and assumed ‘approval’ meant ‘guaranteed safety.’ But I was recently stuck in an elevator for twenty minutes-not life-threatening, but deeply unsettling-and that small feeling of being trapped, of realizing the mechanism designed to protect you had failed, colors everything now. When systems designed for safety fail, the feeling is cold, absolute.

The Substantial Equivalence Trap

So, what does approval actually mean? In too many cases, particularly for medical devices, it means that the company successfully proved their new product is substantially equivalent to an older product that was already on the market. It’s a comparison process, often called 510(k), not a rigorous, independent safety test.

Imagine building a sandcastle and arguing it must be sturdy because the previous one, built last week, didn’t collapse immediately. The foundational flaw is reliance. The FDA, perpetually understaffed and underfunded (Priya’s department hasn’t had a proper increase in 7 years), simply does not have the budget or the manpower to replicate the years of internal testing conducted by a massive corporation with shareholder value at stake.

The Reactive Default

They are reactive, not proactive. They are document processors, not full-time laboratory scientists testing every single batch that hits the shelf. They rely, almost entirely, on the self-reporting data provided by the regulated industry. This isn’t a conspiracy theory; it’s a design flaw built into the regulatory framework itself.

The system prefers speed and market access over exhaustive scrutiny. If we demanded the level of oversight truly required to guarantee zero harm, the pace of innovation would slow to a crawl, and the market would scream. This is the contradiction we live in: we want absolute safety, but we also want the newest, most innovative technology right now.

The Sculptor’s Wisdom

Our regulatory structure is that magnificent, temporary sandcastle. It looks solid, it inspires awe, but the tide (corporate profit motives, political pressure, and sheer volume of submissions) is always coming in. The moment a critical piece of data is missing, or a manufacturer minimizes adverse events in their self-reporting-which they have a powerful financial incentive to do-the castle starts to crumble from the inside. The regulator might not notice until the whole thing is already halfway washed away, sometimes 97 months later.

The Reckoning and Recourse

That crumbling structure is the core reason we see massive, widespread injuries from products that were supposed to be safe. Devices that caused internal injuries, medications that triggered unforeseen catastrophic side effects, or environmental toxins that were minimized during the approval phase. When the system designed to prevent these large-scale harms defaults, where does the injured public turn?

The failure of the FDA to adequately test a defective drug or device means hundreds or thousands of people share the same injury and the same corporate negligence. That’s why organizations dedicated to helping victims navigate these systemic failures become essential, providing a necessary recourse when the government watchdog fails to bark, or worse, takes the treat from the hand of the intruder. Finding the right experts is key to leveling that playing field, which is why resources like the

Mass Tort Intake Center exist.

The Economics of Negligence

If a device manufacturer knows they have a 237-page submission packet and that the reviewer has forty-seven other documents sitting on their desk, the probability of deeply buried flaws being missed goes up dramatically. The risk assessment changes. Why spend millions correcting a flaw that might only cause problems for 7% of users, when the regulatory body is likely to approve based on the initial submission data? The cost of cleaning up the eventual legal mess is simply factored into the price of doing business-it’s cheaper than rigorous pre-market safety testing.

The Human Element Under Pressure

This isn’t to say that everyone in the regulatory world is corrupt. Priya is probably working ninety-hour weeks, fueled by lukewarm coffee and the belief that she is making the world safer. But she is fighting a system designed for compromise, where ‘adequate’ protection is prioritized over ‘absolute’ safety. We project our hopes for safety onto these agencies, but we forget they are staffed by humans operating under incredible constraints, dealing with documents that could literally kill people if they miss one specific data point buried on page 777 of the safety report.

The Ultimate Question

I sometimes think about what real, absolute regulatory oversight would look like in the year 2077. It would involve AI auditing the manufacturer’s internal data in real time, mandatory independent clinical trials financed by a dedicated public trust, and penalties so catastrophic that cutting corners would be unthinkable. But that’s decades away. For now, we operate in the messy middle, where we pretend the initial approval is a shield, when in reality, it’s often just a receipt for paperwork.